What patent covers bempedoic acid, and when does it expire?
Bempedoic acid (brand name Nexletol) is protected by one or more patents covering aspects of the drug and its use, but the exact “expiration date” depends on which specific patent family and jurisdiction you mean. Patent terms can also be affected by factors like patent term adjustments, regulatory exclusivities, and whether a given patent is still in force or has been challenged.
Without a specific patent number (or country such as US vs. EU) there is no single definitive expiry date for “the bempedoic acid patent.”
Where can you look up the exact bempedoic acid patent number and expiry date?
To get the correct expiration date, the usual next step is to look up:
- The drug’s patent listings tied to the brand (for example, in the US via the Orange Book, which lists “patents and exclusivities” for approved drug products).
- The relevant patent documents in the US Patent & Trademark Office (USPTO) or the relevant national/regional patent office (for example, EPO for Europe).
If you share the country (US, EP/EU, UK, etc.) or any patent number you’ve seen, I can narrow down the exact expiration.
Does patent expiry mean generic or biosimilar bempedoic acid can launch immediately?
Not always. Even after patents expire, regulatory exclusivities or remaining listed exclusivities can delay generic entry in some jurisdictions. Also, if patents are still asserted or in litigation, generic launch may be blocked or delayed.
So the timeline for generic availability usually depends on both:
- Which patents remain in force, and
- What regulatory exclusivities apply and whether they have been exhausted.
Are there multiple patents for bempedoic acid (not just one)?
Yes. A single medicine often has multiple patents that cover different things—such as the active ingredient, particular formulations, manufacturing methods, and/or specific uses or dosing regimens. That means “bempedoic acid patent expiry” could refer to different dates for different patent types.
What if you mean the “active ingredient” patent versus formulation/use patents?
These can expire on different schedules. “Active ingredient” patents often cover the core compound; later patents may cover salts, formulations, or specific therapeutic combinations. Generic timelines typically track the latest blocking patent(s) for the relevant approval pathway.
If you want, tell me one detail and I’ll pin down the dates
Reply with either:
1) the country/jurisdiction you care about (US or EU/UK), or
2) a patent number or link you found, or
3) whether you mean Nexletol (bempedoic acid) or a combination product (if applicable),
and I’ll map the specific patent(s) to their expiration date(s).